Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 18, 2017

View Archived Issues

DerG-PG70 LEAPS vaccine suppresses arthritis progression in two Th1 cell-driven murine models

Exenatide has positive effects on motor scores in patients with Parkinson's disease

Promising preclinical data for novel pan-MMP inhibitor-based tracer [99mTc]RYM-1

Cambridge Epigenetix and NuGEN partner to combine leading technologies in epigenetics research

First patient enrolled in phase I study of OTS-167 in breast cancer

Aradigm receives grant to study products in pulmonary non-tuberculous mycobacteria

Medshine Discovery, Jiangsu Chia Tai Tianqing Pharmaceutical patent bile acid receptor agonists

Prometic Life Sciences finalizes joint venture with affiliates of Shenzhen Royal Asset Management

Context Therapeutics enters into collaboration agreements to study Sigma1 protein

Protalex awarded grant to support development of PRTX-100

First patient dosed in phase I/II study of birinapant in combination with Keytruda in solid tumors

Medivir licenses exclusive rights for MIV-802 to Ascletis in greater China

ViraCyte receives CPRIT grant from the Cancer Prevention and Research Institute of Texas

Tetraphase Pharmaceuticals submits marketing application for i.v. eravacycline in Europe

FDA approves Besponsa for adults with relapsed or refractory ALL

First patient dosed in phase I study of UCART-123 in BPDCN

Avadel and Serenity enter into exclusive negotiations for Noctiva

FDA grants new ovarian cancer approvals for Lynparza

Gilead Sciences Canada receives approval notice for Vosevi in refractory HCV

Response submitted to FDA's complete response letter for latanoprostene bunod

Health Canada approves Maviret for chronic HCV in all major genotypes

Hikma expands licensing agreement with Takeda for new products in the Middle East and North Africa

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...